Skip to content

Advertisement

BMC Pulmonary Medicine

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia

  • Masato Tashiro1, 2Email authorView ORCID ID profile,
  • Kiyohide Fushimi3,
  • Kei Kawano2,
  • Takahiro Takazono1, 4,
  • Tomomi Saijo4,
  • Kazuko Yamamoto4,
  • Shintaro Kurihara2,
  • Yoshifumi Imamura4,
  • Taiga Miyazaki1, 4,
  • Katsunori Yanagihara5,
  • Hiroshi Mukae4 and
  • Koichi Izumikawa1, 2
BMC Pulmonary MedicineBMC series – open, inclusive and trusted201717:219

https://doi.org/10.1186/s12890-017-0566-4

Received: 2 May 2017

Accepted: 21 December 2017

Published: 29 December 2017

Abstract

Background

There is conflicting evidence regarding the benefit of adjunctive corticosteroid therapy in patients with Mycoplasma pneumoniae pneumonia. We hypothesised that corticosteroid therapy could reduce mortality and length of stay (LOS) in such patients.

Methods

Adult patients with M. pneumoniae pneumonia from January 2010 to December 2013 were identified from the Japanese Diagnosis Procedure Combination inpatient database. The effects of low-dose and high-dose corticosteroid therapies on mortality, LOS, drug costs and hyperglycaemia requiring insulin treatment were evaluated using propensity score analyses.

Results

Eligible patients (n = 2228) from 630 hospitals were divided into no-corticosteroid (n = 1829), low-dose corticosteroid (n = 267) and high-dose corticosteroid (n = 132) groups. The propensity score-matched pairs were generated from no-corticoid and low-dose corticoid groups (251 pairs), or no-corticoid and high-dose corticosteroid groups (120 pairs). Adjunctive corticosteroid therapy did not decrease 30-day mortality. In addition, both low-dose and high-dose corticosteroid therapies were associated with increases in LOS. Furthermore, hyperglycaemia requiring insulin treatment and drug cost increased with corticosteroid use.

Conclusions

Adjunctive treatment with low-dose or high-dose corticosteroids may not be beneficial in M. pneumoniae pneumonia.

Keywords

Mycoplasma pneumoniae PneumoniaCorticosteroid

Background

Mycoplasma pneumoniae is the cause of 3–10% of pneumonia cases [1] and accounts for 10–30% of all cases of community-acquired pneumonia (CAP) [2, 3]. Most cases of M. pneumoniae pneumonia are mild and self-limiting; however, some result in fulminant respiratory failure and may be fatal [48]. A previous study reported a mortality rate of 29.4% among patients with M. pneumoniae pneumonia who required intensive care unit (ICU) admission [9]. In addition to antimicrobial agents, corticosteroids may be beneficial in the treatment of severe cases of M. pneumoniae infections. This is because the pathogenesis of the disease is related to excessive immune responses, including highly activated cell-mediated immune responses and high expressions of cytokines [1014].

Corticosteroids have been shown to exert a beneficial effect in severe cases of M. pneumoniae infection via downregulation of cell-mediated immune responses associated with the pulmonary injury that occurs during the infection [1518]. However, evidence is limited to case reports and small case series. The results of studies in patients with severe CAP suggest that short-term, late-phase, high-dose corticosteroid treatment is not beneficial [1922]. Conversely, other studies have reported the efficacy of high-dose methylprednisolone therapy in patients with severe M. pneumoniae pneumonia [2326]. In the present study, we hypothesised that adjunctive corticosteroid therapy may reduce mortality and length of stay (LOS) in patients with severe M. pneumoniae pneumonia.

Methods

Data source

We used a large nationwide dataset that was obtained from the Japanese Diagnosis Procedure Combination (DPC) system. The database contains claims and abstracted discharge data from >1000 participating hospitals, including 92% (244/266) of all tertiary hospitals in Japan [27]. The baseline patient information includes age, sex, primary diagnosis and comorbidities at admission, which are coded according to the International Classification of Diseases, 10th revision (ICD-10) [28]. The database also includes the dosages of all drugs and blood products administered during hospitalisation, as well as the dates of treatment administration. In addition, all interventional procedures are coded with original Japanese codes. Dates of hospital admission and discharge, bedside procedures, drugs administered and discharge status (dead or alive) are recorded using a uniform data submission format. Moreover, diagnostic records are linked to the payment system and attending physicians are required to report objective evidence of each diagnosis made for reimbursement of treatment [27]. The DPC is an administrative database with information inputted at discharge. Thus, for the present study, patient follow-up began on the day of admission and ended on the day of discharge, transfer or death. It was impossible to follow up patients thereafter since no subsequent data were entered.

Data were anonymised on extraction and analysed within the protected environment of the Nagasaki University Hospital (Nagasaki, Japan). The Institutional Review Board of Nagasaki University Hospital waived the requirement of informed consent and approved the study design (Institutional Review Board No. 17012303).

Patient selection

We identified patients diagnosed with M. pneumoniae pneumonia from January 2010 to December 2013. During this period, multiple large epidemics of M. pneumoniae infections occurred in Japan [29]. We included patients who were ≥18 years old and had undergone diagnostic tests (paired serologic antibody titres, antigen detection or polymerase chain reaction) confirming M. pneumoniae infection. We restricted the analysis to adults because severe M. pneumoniae infections occur more frequently in the adult and elderly populations [9]. A single antibody titre and cold agglutinins were not included in the diagnostic tests in this study.

The exclusion criteria were as follows: 1) discharge within 2 days of admission, 2) start intravenous corticosteroid therapy after day 2 of admission and 3) existence of any missing data. Low-dose corticosteroid use was defined as the starting dosages an intravenous infusion of methylprednisolone at <125 mg (or an equivalent dose of dexamethasone, hydrocortisone, prednisolone or betamethasone) and any higher dose was defined as a high dose [30].

Variables and endpoints

Comorbidities were evaluated using the Charlson comorbidity index (CCI), which is a method used to predict mortality by classifying or weighting comorbidities [28]. The CCI includes 17 conditions with major impact on survival and is widely used by health researchers to measure case mix and the burden of a disease [31]. For instance, a higher CCI score reflects a more severe comorbidity. The pneumonia severity was evaluated using the A-DROP system, which is the modified CURB-65 scoring system proposed by The Japanese Respiratory Society [32]. It assesses Age (men ≥70 years, women ≥75 years), Dehydration (existence of a clinical sign of dehydration or blood urea nitrogen level ≥ 210 mg/L), Respiratory failure (SpO2 ≤ 90% or PaO2 ≤ 60 mmHg), Orientation disturbance (confusion), and a low blood Pressure (systolic blood pressure ≤ 90 mmHg). The scoring system stratifies patients into four severity classes (mild = 0; moderate = 1–2; severe = 3; and extremely severe = 4–5), and it has an equal ability for predicting the mortality of CAP compared to the CURB-65 scoring system [33]. We assessed medications administered and interventions performed within 2 days of admission except the endpoints.

The endpoints were all-cause 30-day mortality, in-hospital hyperglycaemia needing insulin treatment, LOS, duration of antimicrobial treatment and total costs of all the drugs used. We described cost in terms of Japanese Yen (JPY), Euro (EUR) and US Dollar (USD) (1.00 JPY = 0.008587 EUR, 1.00 JPY = 0.009877 USD).

Statistical analysis

We separately performed one-to-one matching between the no-corticosteroid and the low-dose corticosteroid group, or the no-corticosteroid and the high-dose corticosteroid groups, based on estimated propensity scores for each patient in order to minimise the bias due to confounding variables [31, 34]. To estimate the propensity score, we fitted a logistic regression model for low-dose or high-dose corticosteroid use as a function of patient and hospital demographics, which included age, sex, CCI score, comorbidities (congestive heart failure, renal disease, liver disease, diabetes with/without chronic complications, chronic obstructive pulmonary disease, bronchial asthma, interstitial lung disease and fibrosis, pleural effusion and aspiration or drainage of pleural effusion), parameters of the A-DROP, pneumonia severity, antimicrobial drugs (macrolides, quinolones and tetracyclines), other supportive drugs (catecholamines), interventions (invasive and non-invasive ventilation) and organizational characteristics (ICU admission, academic hospital, and average number of patients in hospital per day) [6, 26, 30, 35, 36]. The catecholamines included dopamine, dobutamine and noradrenaline (norepinephrine). The c-statistic for evaluating the goodness of fit was calculated and a one-to-one matched analysis using nearest-neighbour matching was performed based on the patients’ estimated propensity scores. A match occurred when a patient in the low-dose or high-dose corticosteroid group had an estimated score within 0.2 standard deviations (SDs) of the score of a patient in the no-corticosteroid group [31]. Descriptive statistics have been presented for all patients, including the propensity score-matched patients. Fisher’s exact test or Pearson’s chi-square test was used to compare discrete variables, whereas the Wilcoxon rank-sum test or Kruskal–Wallis test was used for continuous variables. All the statistical analyses were performed using JMP 12.0 software (SAS Institute, Cary, NC, USA). All the tests were two-tailed and a p value <0.05 was considered statistically significant. Data have been expressed as mean ± SD.

Results

Patients

A total of 2718 patients with M. pneumoniae pneumonia were admitted to 690 hospitals from January 2010 to December 2013. Among them, 2390 patients were diagnosed by paired antibody titers, 213 by polymerase chain reaction, and 153 by antigen detection (Fig. 1). Overall, 490 patients were excluded based on the various exclusion criteria previously mentioned. As a result, 2228 patients from 630 hospitals were used in the study and were divided into the following groups: no-corticosteroid (n = 1829), low-dose corticosteroid (n = 267) and high-dose corticosteroid (n = 132). From the aforementioned data, the low-dose and high-dose corticosteroid propensity score-matched pairs that were generated were 247 and 122, respectively (Fig. 1). The c-statistic analysis indicated that the goodness of fit values were 0.79 and 0.83 for the low-dose and high-dose groups, respectively, according to the propensity score model.
Fig. 1

Patient selection

Table 1 shows the baseline characteristics of the unmatched groups. When the unmatched groups were compared, patients who had more complex comorbidities (i.e., those who were treated with quinolones or were in serious condition and required supportive treatment, mechanical ventilation or care in an ICU) were more likely to receive a corticosteroid treatment. Especially, patients who had bronchial asthma tended to require low-dose corticosteroids (41.2%), whereas those who had interstitial lung disease tended to require high-dose corticosteroids (25.8%). After propensity score-matching, the baseline patient characteristics were similar between the no-corticosteroid (n = 251) and low-dose corticosteroid groups (n = 251), as well as between the no-corticosteroid (n = 120) and high-dose corticosteroid groups (n = 120) (Tables 2 and 3).
Table 1

Baseline patient and organization characteristics in the unmatched groups

Characteristic

No corticosteroid

Low-dose corticosteroids

High-dose corticosteroids

 

n = 1829

n = 267

n = 132

p value

Patient Characteristics

Age, years

49.2

±22.6

49.8

±21.1

53.7

±22.3

0.0760

Male

847

(46.3)

106

(39.7)

69

(52.3)

0.0405

Preexisting comorbid conditions

 Charlson comorbidity index

0.63

±1.0

1.17

±1.2

0.88

±0.9

< 0.0001

 Congestive heart failure

108

(5.9)

35

(13.1)

10

(7.6)

< 0.0001

 Renal disease

32

(1.8)

3

(1.1)

2

(1.5)

0.7493

 Liver disease

92

(5.0)

5

(1.9)

6

(4.5)

0.0717

 Diabetes without chronic complications

144

(7.9)

25

(9.4)

17

(12.9)

0.1086

 Diabetes with chronic complications

33

(1.8)

6

(2.2)

1

(0.8)

0.5723

 Chronic obstructive pulmonary disease

85

(4.6)

22

(8.2)

8

(6.1)

0.0413

 Bronchial asthma

157

(8.6)

110

(41.2)

31

(23.5)

< 0.0001

 Interstitial lung disease and fibrosis

62

(3.4)

19

(7.1)

34

(25.8)

< 0.0001

 Pleural effusion

117

(6.4)

14

(5.2)

11

(8.3)

0.4910

 Aspiration or drainage of pleural effusion

4

(0.2)

3

(1.1)

2

(1.5)

0.0108

Pneumonia characteristics

Parameters of the A-DROP

 Age (male ≥ 70 years, female ≥ 75 years)

473

(25.9)

58

(21.7)

43

(32.6)

0.0642

 Dehydration

201

(11.0)

39

(14.6)

19

(14.4)

0.1344

 Confusion

196

(10.7)

63

(23.6)

56

(42.4)

< 0.0001

 Respiratory failure

38

(2.1)

12

(4.5)

8

(6.1)

0.0025

 Low blood pressure

176

(9.6)

37

(13.9)

17

(12.9)

0.0638

Pneumonia severity

 Mild

1110

(60.7)

137

(51.3)

48

(36.4)

< 0.0001

 Moderate

645

(35.3)

111

(41.6)

75

(56.8)

 

 Severe

58

(3.2)

14

(5.2)

6

(4.5)

 

 Extremely severe

16

(0.9)

5

(1.9)

3

(2.3)

 

Other treatments

Anti-mycoplasmal drug use

 Macroride

695

(38.0)

104

(39.0)

49

(37.1)

0.9314

 Quinolone

548

(30.0)

116

(43.4)

69

(52.3)

< 0.0001

 Tetracycline

569

(31.1)

78

(29.2)

30

(22.7)

0.1172

Other supportive drug use

 Catecholamine

13

(0.7)

5

(1.9)

8

(6.1)

< 0.0001

Interventions

 Invasive ventilation

10

(0.5)

5

(1.9)

12

(9.1)

< 0.0001

 Non-invasive ventilation

2

(0.1)

 

(0.0)

2

(1.5)

0.0009

Organization characteristics

Intensive care unit admission

8

(0.4)

5

(1.9)

10

(7.6)

< 0.0001

Academic hospital

131

(7.2)

16

(6.0)

17

(12.9)

0.0345

Average number of patients in hospital per day

 ≤ 200

351

(19.2)

40

(15.0)

26

(19.7)

0.2502

 201–600

1194

(65.3)

190

(71.2)

81

(61.4)

 

 ≥ 601

284

(15.5)

37

(13.9)

25

(18.9)

 

Data are shown as n (%) or mean ± SD (standard deviation)

Table 2

Baseline patient and organization characteristics in the matched groups of no corticosteroid and low-dose corticosteroid

Characteristic

No corticosteroid

Low-dose corticosteroids

 

n = 251

n = 251

p value

Patient Characteristics

Age, years

49.9

±21.6

49.6

±21.5

0.8753

Male

110

(43.8)

101

(40.2)

0.4695

Preexisting comorbid conditions

 Charlson comorbidity index

1.25

±1.3

1.08

±1.1

0.1921

 Congestive heart failure

30

(12.0)

30

(12.0)

1.0000

 Renal disease

5

(2.0)

3

(1.2)

0.7244

 Liver disease

6

(2.4)

5

(2.0)

1.0000

 Diabetes without chronic complications

27

(10.8)

25

(10.0)

0.8837

 Diabetes with chronic complications

8

(3.2)

6

(2.4)

0.7875

 Chronic obstructive pulmonary disease

25

(10.0)

20

(8.0)

0.5324

 Bronchial asthma

103

(41.0)

96

(38.2)

0.5841

 Interstitial lung disease and fibrosis

12

(4.8)

16

(6.4)

0.5603

 Pleural effusion

12

(4.8)

13

(5.2)

1.0000

 Aspiration or drainage of pleural effusion

2

(0.8)

2

(0.8)

1.0000

Pneumonia characteristics

Parameters of the A-DROP

 Age (male ≥70 years, female ≥75 years)

61

(24.3)

57

(22.7)

0.7523

 Dehydration

40

(15.9)

35

(13.9)

0.6167

 Confusion

47

(18.7)

54

(21.5)

0.5043

 Respiratory failure

8

(3.2)

9

(3.6)

1.0000

 Low blood pressure

29

(11.6)

31

(12.4)

0.8907

Pneumonia severity

 Mild

137

(54.6)

135

(53.8)

0.9527

 Moderate

97

(38.6)

100

(39.8)

 

 Severe

13

(5.2)

11

(4.4)

 

 Extremely severe

4

(1.6)

5

(2.0)

 

Other treatments

Anti-mycoplasmal drug use

 Macroride

89

(35.5)

94

(37.5)

0.7107

 Quinolone

104

(41.4)

106

(42.2)

0.9279

 Tetracycline

68

(27.1)

75

(29.9)

0.5531

Other supportive drug use

 Catecholamine

4

(1.6)

4

(1.6)

1.0000

Interventions

 Invasive ventilation

5

(2.0)

4

(1.6)

1.0000

 Non-invasive ventilation

0

(0.0)

0

(0.0)

 

Organization characteristics

Intensive care unit admission

4

(1.6)

5

(2.0)

1.0000

Academic hospital

12

(4.8)

15

(6.0)

0.6931

Average number of patients in hospital per day

 ≤ 200

44

(17.5)

40

(15.9)

0.7962

 201–600

169

(67.3)

176

(70.1)

 

 ≥ 601

38

(15.1)

35

(13.9)

 

Data are shown as n (%) or mean ± SD (standard deviation)

Table 3

Baseline patient and organization characteristics in the matched groups of no corticosteroid and high-dose corticosteroid

Characteristic

No corticosteroid

High-dose corticosteroids

 

n = 120

n = 120

p value

Patient Characteristics

Age, years

55.2

±22.7

52.5

±22.5

0.3607

Male

65

(54.2)

63

(52.5)

0.8971

Preexisting comorbid conditions

 Charlson comorbidity index

1.01

±1.1

0.90

±0.9

0.6511

 Congestive heart failure

11

(9.2)

9

(7.5)

0.8160

 Renal disease

1

(0.8)

2

(1.7)

1.0000

 Liver disease

4

(3.3)

6

(5.0)

0.7486

 Diabetes without chronic complications

15

(12.5)

14

(11.7)

1.0000

 Diabetes with chronic complications

 

(0.0)

1

(0.8)

1.0000

 Chronic obstructive pulmonary disease

11

(9.2)

8

(6.7)

0.6336

 Bronchial asthma

39

(32.5)

30

(25.0)

0.2538

 Interstitial lung disease and fibrosis

23

(19.2)

24

(20.0)

1.0000

 Pleural effusion

10

(8.3)

10

(8.3)

1.0000

 Aspiration or drainage of pleural effusion

1

(0.8)

1

(0.8)

1.0000

Pneumonia characteristics

Parameters of the A-DROP

 Age (male ≥70 years, female ≥75 years)

40

(33.3)

36

(30.0)

0.6773

 Dehydration

22

(18.3)

18

(15.0)

0.6037

 Confusion

43

(35.8)

45

(37.5)

0.8935

 Respiratory failure

6

(5.0)

6

(5.0)

1.0000

 Low blood pressure

23

(19.2)

16

(13.3)

0.2937

Pneumonia severity

 Mild

45

(37.5)

48

(40.0)

0.7779

 Moderate

64

(53.3)

64

(53.3)

 

 Severe

5

(4.2)

5

(4.2)

 

 Extremely severe

6

(5.0)

3

(2.5)

 

Other treatments

Anti-mycoplasmal drug use

 Macroride

44

(36.7)

45

(37.5)

1.0000

 Quinolone

49

(40.8)

59

(49.2)

0.2429

 Tetracycline

28

(23.3)

28

(23.3)

1.0000

Other supportive drug use

 Catecholamine

8

(6.7)

5

(4.2)

0.5702

Interventions

 Invasive ventilation

7

(5.8)

7

(5.8)

1.0000

 Non-invasive ventilation

1

(0.8)

2

(1.7)

1.0000

Organization characteristics

Intensive care unit admission

5

(4.2)

6

(5.0)

1.0000

Academic hospital

11

(9.2)

15

(12.5)

0.5339

Average number of patients in hospital per day

 ≤ 200

18

(15.0)

23

(19.2)

0.6922

 201–600

79

(65.8)

75

(62.5)

 

 ≥ 601

23

(19.2)

22

(18.3)

 

Data are shown as n (%) or mean ± SD (standard deviation)

The durations of intravenous corticosteroid use were 3.8 ± 9.7 days (unmatched group) and 3.4 ± 9.4 days (matched group) in the low-dose corticosteroid group, and 2.8 ± 3.6 days (unmatched group) and 2.9 ± 3.6 days (matched group) in the high-dose corticosteroid group. The stated durations included the periods of tapered low-dose corticosteroid use. The starting dosages of methylprednisolone were 56.3 ± 39.4 mg/day (unmatched group) and 55.7 ± 39.7 mg/day (matched group) in the low-dose corticosteroid group, and 622 ± 422 mg/day (unmatched group) and 603 ± 430 mg/day (matched group) in the high-dose corticosteroid group.

Endpoints

The outcomes in the unmatched groups showed a higher 30-day mortality rate (5.3%) in the high-dose corticosteroid group than in the no-corticosteroid group (0.8%) or low-dose corticosteroid group (1.9%) (p < 0.0001) (Table 4). Furthermore, the occurrence of in-hospital hyperglycaemia that required insulin treatment, which is an important adverse effect of corticosteroid therapy, was significantly higher at higher corticosteroid dosages (5.7, 11.2 and 23.5% for the no-corticosteroid, low-dose corticosteroid and high-dose corticosteroid groups, respectively). In addition, LOS significantly increased as corticosteroid dosage was increased (13.1 ± 12.8, 18.0 ± 18.8 and 23.6 ± 18.5 days for the no-corticosteroid, low-dose corticosteroid and high-dose corticosteroid groups, respectively). Moreover, the duration of antimicrobial treatment was longer in the low-dose and high-dose corticosteroid groups (9.3 ± 7.3 and 9.5 ± 6.3 days, respectively) than in the no-corticosteroid group (6.8 ± 4.8 days) (p < 0.001). The total cost of all drugs administered during hospitalisation was higher in the corticosteroid-treated groups than in the no-corticosteroid group (p < 0.0001).
Table 4

Comparisons of outcomes between unmatched groups

Characteristic

No corticosteroid

Low-dose corticosteroids

High-dose corticosteroids

 

n = 1829

n = 267

n = 132

p value

30-day mortality

14

(0.8)

5

(1.9)

7

(5.3)

< 0.0001

In-hospital hyperglycemia requiring insulin treatment

104

(5.7)

30

(11.2)

31

(23.5)

< 0.0001

Length of stay, days

13.1

±12.8

18.0

±18.8

23.6

±18.5

< 0.0001

Length of anitmicrobial treatment, days

6.8

±4.8

9.3

±7.3

9.5

±6.3

< 0.0001

Total cost of all drugs in hospitalization

 Japanese Yen ± SD

49,799

±99,142

107,656

±243,792

161,980

±225,494

< 0.0001

 Euro ± SD

428

±851

924

±2093

1391

±1936

 

 US Dollar ± SD

492

±979

1063

±2408

1600

±2227

 

Data are shown as n (%) or mean ± SD (standard deviation)

1.00 Japanese Yen = 0.008587 Euro

1.00 Japanese Yen = 0.009877 US Dollar

In the propensity score-matched groups, low-dose corticosteroid therapy was associated with a long LOS, a long antimicrobial treatment, and a high total cost of drug treatment (Table 5). There were no statistical differences in 30-day mortality and hyperglycaemia requiring insulin treatment in the propensity score analysis between the no-corticosteroid and low-dose corticosteroid groups.
Table 5

Comparisons of outcomes between matched groups of no corticosteroid and low-dose corticosteroid

Characteristic

No corticosteroid

Low-dose corticosteroids

 

n = 251

n = 251

p value

30-day mortality

5

(2.0)

5

(2.0)

1.0000

In-hospital hyperglycemia requiring insulin treatment

20

(8.0)

30

(12.0)

0.1794

Length of stay, days

12.8

±9.1

17.6

±18.0

0.0055

Length of anitmicrobial treatment, days

7.1

±5.1

8.9

±6.7

0.0026

Total cost of all drugs in hospitalization

 Japanese Yen ± SD

63,265

±142,385

103,566

±237,757

< 0.0001

 Euro ± SD

543

±1223

889

±2042

 

 US Dollar ± SD

625

±1406

1023

±2348

 

Data are shown as n (%) or mean ± SD (standard deviation)

1.00 Japanese Yen = 0.008587 Euro

1.00 Japanese Yen = 0.009877 US Dollar

The high-dose corticosteroid group also showed a long LOS, a long antimicrobial treatment and a high total cost of drug treatment (Table 6). There was no statistical difference in 30-day mortality between the no-corticosteroid and high-dose corticosteroid groups. However, an extremely high prevalence of hyperglycaemia requiring insulin treatment was seen in the high-dose corticosteroid group (5.0% [no-corticosteroid] vs 21.7% [high-dose corticosteroid], p = 0.0002).
Table 6

Comparisons of outcomes between matched groups of no corticosteroid and high-dose corticosteroid

Characteristic

No corticosteroid

High-dose corticosteroids

 

n = 122

n = 122

p value

30-day mortality

4

(3.3)

6

(5.0)

0.7486

In-hospital hyperglycemia requiring insulin treatment

6

(5.0)

26

(21.7)

0.0002

Length of stay, days

15.4

±17.8

22.8

±18.2

< 0.0001

Length of anitmicrobial treatment, days

6.9

±5.2

9.4

±6.4

0.0005

Total cost of all drugs in hospitalization

 Japanese Yen ± SD

94,905

±222,024

145,767

±203,214

< 0.0001

 Euro ± SD

815

±1907

1252

±1745

 

 US Dollar ± SD

937

±2193

1440

±2007

 

Data are shown as n (%) or mean ± SD (standard deviation)

1.00 Japanese Yen = 0.008587 Euro

1.00 Japanese Yen = 0.009877 US Dollar

Discussion

Based on our hypothesis, our aim was to demonstrate the beneficial effects of adjunctive corticosteroid therapy for M. pneumoniae pneumonia. Before conducting this analysis, we had expected that this adjunct therapy could rapidly improve the systemic symptoms of patients and shorten hospitalisation and decrease total treatment costs. However, contrary to our hypothesis, we found that adjunctive treatment with either low-dose or high-dose corticosteroids was associated with a longer LOS and a higher cost of drug treatment during hospitalisation. This means that patients who were administered corticosteroids were not discharged earlier than those who were not administered corticosteroids were. Moreover, a longer LOS is likely to result in the administration of more drugs, which increases the cost of pharmacological treatment. Furthermore, physicians administered corticosteroids as an adjunct therapy in severe cases or to patients who had bronchial asthma or interstitial lung disease. Indeed, from the unmatched group analysis, we found that disease severity was significantly greater in the corticosteroid groups than in the no-corticosteroid group, which clearly influenced mortality, LOS and other outcomes. Hence, we performed a propensity-matched analysis to balance out the outcomes of disease severity. LOS and total drug cost were still higher in the corticosteroid groups than in the no-corticosteroid group. We observed that adjunctive corticosteroid therapy could not reduce LOS or total drug costs although clinicians have observed clinical improvements immediately after administering corticosteroids in some cases [25]. Our results do not necessarily conflict with the outcomes stated in the aforementioned report, which indicated early beneficial effects of adjunctive corticosteroid treatment. This is because later outcomes such as LOS and total drug costs were not stated in the report. In addition, we did not observe a decrease in mortality in the corticosteroid-treated patients, which is a difficult outcome to assess because of the low mortality rate from M. pneumoniae infections.

Recent randomised controlled trials (RCTs) and cohort studies that evaluated the use of corticosteroids in adult patients with CAP showed the possibility of obtaining beneficial effects from the treatment, such as decreased treatment failure and shortened time to achieve clinical stability [35, 36]. This call for the use of steroids during the treatment of patients with pneumonia is relevant since M. pneumoniae is one of the two most common respiratory pathogens [35]. However, the results from our study do not corroborate those of some previous studies. Torres et al. showed that acute administration of methylprednisolone for patients with severe community-acquired pneumonia and high initial inflammatory response was associated with few treatment failures and low inflammatory responses [35]. Our study included pneumonia patients regardless of the degree of inflammation because we could not use C-reactive protein which is a marker of the inflammation despite we tried to adjust pneumonia severity by using A-DROP system. These differences of results between previous studies and our study indicate that adjunctive steroid therapy could be beneficial in particular cases and that inadequate steroid administration might lead to unfavourable effects.

The main strength and the most important characteristic of our study, which makes it unique from previous studies, is that we analysed the effects of corticosteroid therapy in three groups of patients. Recent studies have focused on only low-dose corticosteroid therapy; however, the efficacy of high-dose methylprednisolone therapy has also been reported for the treatment of severe M. pneumoniae pneumonia [2326]. Therefore, we analysed the efficacy of corticosteroids as an adjunctive therapy at both low and high doses. However, our findings indicate that high-dose corticosteroid therapy might induce several adverse effects, including hyperglycaemia, which might result in a longer LOS and a higher drug cost due to the need to manage the adverse effects with drugs. These results might apply to the treatment of CAP as well.

This study has some limitations. Firstly, many of the diagnoses of M. pneumoniae pneumonia were made based on paired antibody titres. Therefore patients with longer LOS were selected for this analysis, which could be considered as selection bias. Indeed, the mean LOS in this study was longer than 2 weeks. However, the abovementioned limitation affected the no-corticosteroid and corticosteroid-treated groups in similar manners. Secondly, although we used a nationwide database, our study was retrospective, observational and conducted without randomisation. Moreover, bias arising from unmeasured confounders, such as clinical variables and laboratory values, may have been present although we used propensity score matching to adjust for differences in baseline characteristics and disease severity [21, 35]. Therefore, large randomised trials are necessary to confirm these results; however, it may not be easy to perform such trials considering that life-threatening M. pneumoniae pneumonia is a rare condition. Thus, the present study may provide the best attainable level of evidence on the issue under discussion. Thirdly, there is a possibility that the study population included some patients with bacterial pneumonia caused by other bacteria in addition to M. pneumoniae. However, in routine clinical settings it is difficult to exclude co-infection with other pathologic bacteria in patients diagnosed with severe M. pneumoniae pneumonia.

Conclusions

We found that adjunctive treatment with either low-dose or high-dose corticosteroids may not be beneficial in patients with M. pneumoniae pneumonia. Based on these findings, clinicians should be more careful if they use corticosteroids to treat adult inpatients with M. pneumoniae pneumonia.

Abbreviations

CCI: 

Charlson comorbidity index

CI: 

Confidence interval

DPC: 

Japanese Diagnosis Procedure Combination

ICD-10: 

International Classification of Diseases, tenth revision codes

JCS: 

Japan Coma Scale

LOS: 

Length of stay

OR: 

Odds ratio

SD: 

Standard deviation

Declarations

Acknowledgements

We thank Eishi Ikeda for the advice on the conception of the study.

Funding

This work was supported by a Grant-in-Aid for Research on Policy Planning and Evaluation from the Ministry of Health, Labour and Welfare (Japan) (H26-Seisaku-Shitei-011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

We obtained data from a large, nationwide dataset of the Japanese Diagnosis Procedure Combination system. This dataset was populated from our survey of DPC hospitals; all voluntarily participated (with non-disclosure agreements). Public access to the DPC database is not permitted; the database is for confidential use by our study group. Therefore the raw data in this study cannot be shared.

Authors’ contributions

Study concept, design, data analysis, and manuscript drafting: MT. Data acquisition: KF. Study supervision and critical revision of the manuscript for important intellectual content: KK, TT, TS, K. Yamamoto, SK, YI, TM, K. Yanagihara, HM, and KI. Final approval: MT, KF, KK, TT, TS, K. Yamamoto, SK, YI, TM, K. Yanagihara, HM, and KI. All authors read and approved the final manuscript.

Ethics approval and consent to participate

We confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript. The Institutional Review Board of Nagasaki University Hospital waived the requirement of informed consent and approved the study design (Institutional Review Board No. 17012303).

Consent for publication

Not applicable

Competing interests

All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
(2)
Nagasaki University Infection Control and Education Centre, Nagasaki University Hospital, Nagasaki, Japan
(3)
Department of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
(4)
Second Department of Internal Medicine, Nagasaki University Hospital, Nagasaki, Japan
(5)
Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

References

  1. Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr. Mycoplasma pneumoniae pneumonia. Chest. 1989;95(3):639–46.View ArticlePubMedGoogle Scholar
  2. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697–728.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M. A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology. J Infect Chemother. 2004;10(6):359–63.View ArticlePubMedGoogle Scholar
  4. Kannan TR, Hardy RD, Coalson JJ, Cavuoti DC, Siegel JD, Cagle M, Musatovova O, Herrera C, Baseman JB. Fatal outcomes in family transmission of Mycoplasma pneumoniae. Clin Infect Dis. 2012;54(2):225–31.View ArticlePubMedGoogle Scholar
  5. Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia. Front Microbiol. 2016;7:800.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobashi Y, Oka M. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol. 2007;56(Pt 12):1625–9.View ArticlePubMedGoogle Scholar
  7. Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PLoS One. 2016;11(5):e0156465.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Wang M, Wang Y, Yan Y, Zhu C, Huang L, Shao X, Xu J, Zhu H, Sun X, Ji W, et al. Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children. Int J Infect Dis. 2014;29:18–23.View ArticlePubMedGoogle Scholar
  9. Khoury T, Sviri S, Rmeileh AA, Nubani A, Abutbul A, Hoss S, van Heerden PV, Bayya AE, Hidalgo-Grass C, Moses AE, et al. Increased rates of intensive care unit admission in patients with Mycoplasma pneumoniae: a retrospective study. Clin Microbiol Infect. 2016;22(8):711–4.View ArticlePubMedGoogle Scholar
  10. Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H, Wakabayashi T, Nakano T, Ouchi K, Okimoto N. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2015;21(3):153–60.View ArticlePubMedGoogle Scholar
  11. Tanaka H, Narita M, Teramoto S, Saikai T, Oashi K, Igarashi T, Abe S. Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest. 2002;121(5):1493–7.View ArticlePubMedGoogle Scholar
  12. Narita M, Tanaka H, Abe S, Yamada S, Kubota M, Togashi T. Close association between pulmonary disease manifestation in Mycoplasma pneumoniae infection and enhanced local production of interleukin-18 in the lung, independent of gamma interferon. Clin Diagn Lab Immunol. 2000;7(6):909–14.PubMedPubMed CentralGoogle Scholar
  13. Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F, Li S, Fu Z. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2014;49(4):377–80.View ArticlePubMedGoogle Scholar
  14. Huang L, Gao X, Chen M. Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial. J Trop Pediatr. 2014;60(5):338–42.View ArticlePubMedGoogle Scholar
  15. Kawamata R, Yokoyama K, Sato M, Goto M, Nozaki Y, Takagi T, Kumagai H, Yamagata T. Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia. J Infect Chemother. 2015;21(11):783–9.View ArticlePubMedGoogle Scholar
  16. Inamura N, Miyashita N, Hasegawa S, Kato A, Fukuda Y, Saitoh A, Kondo E, Teranishi H, Wakabayashi T, Akaike H, et al. Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother. 2014;20(4):270–3.View ArticlePubMedGoogle Scholar
  17. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, Gomez AM, Esposito S, Principi N, Hardy RD. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008;198(8):1180–8.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Remmelts HH, Meijvis SC, Biesma DH, van Velzen-Blad H, Voorn GP, Grutters JC, Bos WJ, Rijkers GT. Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia. Clin Vaccine Immunol. 2012;19(9):1532–8.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317(25):1565–70.View ArticlePubMedGoogle Scholar
  20. Cheng M, Pan ZY, Yang J, Gao YD. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care. 2014;59(4):557–63.View ArticlePubMedGoogle Scholar
  21. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, Voorn GP, van de Garde EM, Endeman H, Grutters JC, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023–30.View ArticlePubMedGoogle Scholar
  22. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 2012;7(10):e47926.View ArticlePubMedPubMed CentralGoogle Scholar
  23. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of Methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res. 2014;6(1):22–6.View ArticlePubMedGoogle Scholar
  24. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Inf Secur. 2008;57(3):223–8.Google Scholar
  25. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis. 2000;31(6):1507–11.View ArticlePubMedGoogle Scholar
  26. Izumikawa K, Izumikawa K, Takazono T, Kosai K, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyazaki T, Tsukamoto M, et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother. 2014;20(3):181–5.View ArticlePubMedGoogle Scholar
  27. Tagami T, Matsui H, Fushimi K, Yasunaga H. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Dis. 2015;61(3):385–92.View ArticlePubMedGoogle Scholar
  28. Sundararajan V, Quan H, Halfon P, Fushimi K, Luthi JC, Burnand B, Ghali WA. International methodology consortium for coded health I: cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care. 2007;45(12):1210–5.View ArticlePubMedGoogle Scholar
  29. Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for Macrolide-Resistant M. pneumoniae. Front Microbiol. 2016;7:693.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J. 2015;45(2):463–72.View ArticlePubMedGoogle Scholar
  31. Tagami T, Matsui H, Fushimi K, Yasunaga H. Prophylactic antibiotics may improve outcome in patients with severe burns requiring mechanical ventilation: propensity score analysis of a Japanese Nationwide database. Clin Infect Dis. 2016;62(1):60–6.View ArticlePubMedGoogle Scholar
  32. Committee for The Japanese Respiratory Society guidelines for the management of respiratory i. Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology. 2006;11(Suppl 3):S79–133.Google Scholar
  33. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K, Hasegawa Y. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology. 2008;13(5):731–5.View ArticlePubMedGoogle Scholar
  34. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297(3):278–85.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrus A, Sellares J, Restrepo MI, Anzueto A, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677–86.View ArticlePubMedGoogle Scholar
  36. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement